Srdan Verstovsek, MD, PhD, discusses the main reasons for his study on the use of rusfertide in patients with polycythemia vera.
Srdan Verstovsek, MD
Advertisement
Articles by Srdan Verstovsek, MD
Srdan Verstovsek, MD, of MD Anderson Cancer Center, discusses a study of sotatercept (ACE-011) alone and in combination with ruxolitinib in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.
Advertisement
Latest Updated Articles
Can Rusfertide Eliminate Need For Phlebotomy in Polycythemia Vera Treatment?Published: February 8th 2022 | Updated:
Sotatercept in Patients With MPN-Associated Myelofibrosis and AnemiaPublished: December 16th 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
